MARKETS / NASDAQ / NUWE
NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Nuwellis, Inc. NUWE

15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$8.3M
▼ 5.4% vs FY2024
EPS · FY25
$-25.39
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-382.9%
Net margin · FY25
-211.9%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 8.3M
Revenue, FY2025 · full 15-year series below
Revenue Net income
0.00250.0050.00750.010.0-0.0201120142017202020232025
0.00250.0050.00750.010.0-0.02016201920222025

The company lost 212 cents on every revenue dollar this year.

Per share
USD -25.39
Diluted EPS, FY2025
EPS
0.40.81.2-25.39201120142017202020232025
0.40.81.2-25.392016201920222025

The company pays no cash dividend.

Profitability
-382.9%
Return on equity, FY2025
ROE
0.250.50.751-382.9%201120142017202020232025
0.250.50.751-382.9%2016201920222025
Operating margin-134.3%
Net margin-211.9%
Return on assets-219.3%

Each USD of equity lost 383 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+2.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−1.1%
+2.1%
+63.9%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.00B
Shares outstanding, FY2025
0.010.00201120142017202020232025
0.000.002016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 6.1M
total assets, end of FY2025
Total assetsUSD 6.1M
EquityUSD 2.6M
CashUSD 1.1M
Current ratio1.71×

Equity funds 43% of total assets.

History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−25.39
−353.30
−360.06
−83.55
−285.36
−10.67
−278.90
−42.14
−525.01
−536.12
−44.01
−1.51
−1.71
−1.98
−2.98
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−382.9
−234.6
−263.4
−75.8
−92.5
−173.0
−457.1
−153.6
−148.7
−226.8
−128.5
−63.2
−67.3
−160.3
−352.4
Shares out B
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.02
0.02
0.01
0.01

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
51 of 51
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed